



Patient Access

Infection Prevention with Certofix[®] protect

Technical brochure of a non-leaching central venous catheter

Certofix® protect

for optimizing catheter care




Anti-pathogenic Certofix® protect catheters


The protect coating creates a catheter surface with very good anti-pathogenic characteristics. The adhesion of bacteria, which is normally the starting point of a catheter-related bloodstream infection, is effectively prevented in this non-leaching catheter.

The functional principle of Certofix® protect


The polarization of the Certofix® protect catheter surface destroys the cell membrane structure of microorganisms in the event of surface contact. Ongoing chemical interaction between the catheter material (PUR) and the protect coating ensures long-term protection without leaching effect. Certofix® protect prevents catheter-related infections during the entire application period.²²



Ongoing chemical interaction between polarized catheter material and antimicrobial agent.



The antimicrobial inner and outer surface makes for a non-leaching catheter.




The cell wall structure of microorganisms is destroyed.



USER BENEFITS

- A non-leaching antimicrobial central venous catheter
- No active agents are released, long time efficiency up to 30 days²²
- The same flexibility as other Certofix® catheters
- Total catheter surface coverage – from tip to hub: On the complete inner surface and outside up to the channel junction



Efficacy of Certofix® protect²²

The same test results were obtained for:

- Escherichia coli, Enterococcus faecalis
- Klebsiella pneumoniae
- Candida albicans

Efficacy of Certofix® protect in long-term use

The anti-pathogenic characteristics (30 days) of non-leaching antimicrobial central venous catheters on 7 typical CVC-associated infection bacteria was tested with the "Roll-Out" method, (Staphylococcus epidermidis, Staphylococcus aureus MRSA and E. coli, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Candida albicans).

"Roll-Out" test shows the following results

- The in-vitro trial demonstrates that Certofix® protect exhibits antimicrobial efficacy and prevents biofilm formation from gram-positive, gram-negative bacteria and fungi for up to 30 days.²²
- The study was performed in direct comparison with a non-antimicrobial control catheter, on which all 7 test strains were able to grow to an established surface biofilm.²²

Summary

This is the first in-vitro study to demonstrate antibacterial surface activity and prevention of biofilm formation with antimicrobial, non-leaching CVCs by using the "Roll-Out" method over a period of 30 days. These results demonstrate that non-leaching antimicrobial CVCs can prevent microbial colonization and infection.

PRESCRIPTION

PATIENT ACCESS

PREPARATION

APPLICATION

DISCHARGE MANAGEMENT

Literature

1. Satorius AE, Szafranski J, Pyne D, Ganesan M, Solomon MJ, Newton DW, Bortz DM, Younger JG. Complement c5a generation by staphylococcal biofilms. *Shock*. 2013 Apr; 39(4):336-42
2. Elliott TSJ. The pathogenesis and prevention of intravascular catheter-related infections. In: Hamilton H, Bodenham AR. *Central venous catheters*. Chichester [u.a.]: Wiley-Blackwell 2009; 206-209
3. Ebert T, Smith S, Pancari G, Wu X, Zorman J, Clark D, Cook J, Burns C, Antonello JM, Cope L, Nagy E, Meinke A, McNeely T. Development of a rat central venous catheter model for evaluation of vaccines to prevent *Staphylococcus epidermidis* and *Staphylococcus aureus* early biofilms. *Hum Vaccin*. 2011 Jun; 7(6):630-8
4. Walz JM, Memtsoudis SG, Heard SO. Prevention of central venous catheter bloodstream infections. *J Intensive Care Med*. 2010 May-Jun; 25(3):131-8
5. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE; Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheter-related infections. *Clin Infect Dis*. 2001 May 1; 32(9):1249-72
6. Yousif A, Jamal MA, Raad I. Biofilm-based central line-associated bloodstream infections. *Adv Exp Med Biol*. 2015; 830:157-79
7. Nakamura I1, Fukushima S2, Hayakawa T2, Sekiya K3, Matsumoto T4. The additional costs of catheter-related bloodstream infections in intensive care units. *Am J Infect Control*. 2015 Oct 1; 43(10):1046-9
8. Frampton GK, Harris P, Cooper K, Cooper T, Cleland J, Jones J, Shepherd J, Clegg A, Graves N, Welch K, Cuthbertson BH. Educational interventions for preventing vascular catheter bloodstream infections in critical care: evidence map, systematic review and economic evaluation. *Health Technol Assess*. 2014 Feb; 18(15):1-365
9. Walder B, Pittet D, Tramèr MR. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. *Infect Control Hosp Epidemiol*. 2002 Dec; 23(12):748-56
10. The Joint Commission. *Preventing Central Line-Associated Bloodstream Infections: A Global Challenge, a Global Perspective*. Oak Brook, IL: Joint Commission Resources, May 2012. [Online]
11. Worth LJ, McLaws ML. Is it possible to achieve a target of zero central line associated bloodstream infections? *Curr Opin Infect Dis*. 2012 Dec; 25(6):650-7
12. O'Grady NP, Alexander M, Burns LA et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections. CDC. *Guidelines for the Prevention of Intravascular Catheter-Related Infections*. Centers for Disease Control and Prevention. 2011
13. McLaws ML, Burrell AR. Zero risk for central line-associated bloodstream infection: are we there yet? *Crit Care Med*. 2012 Feb; 40(2):388-93
14. Milstone AM, Sengupta A. Do prolonged peripherally inserted central venous catheter dwell times increase the risk of bloodstream infection? *Infect Control Hosp Epidemiol*. 2010 Nov; 31(11):1184-7
15. McLaws ML, Berry G. Nonuniform risk of bloodstream infection with increasing central venous catheter-days. *Infect Control Hosp Epidemiol*. 2005 Aug; 26(8):715-9
16. Guleri A, Kumar A, Morgan RJ, Hartley M, Roberts DH. Anaphylaxis to chlorhexidine-coated central venous catheters: a case series and review of the literature. *Surg Infect (Larchmt)*. 2012 Jun; 13(3):171-4
17. Yasukawa T, Fujita Y, Sari A. Antimicrobial-impregnated central venous catheters. *N Engl J Med*. 1999 Jun 3; 340(22):1762
18. Oda T, Hamasaki J, Kanda N, Mikami K. Anaphylactic shock induced by an antiseptic-coated central venous catheter. *Anesthesiology*. 1997 Nov; 87(5):1242-4
19. Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant *Staphylococcus bacteremic* isolates embedded in biofilm. *Antimicrob Agents Chemother*. 2007 May; 51(5):1656-60
20. Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. *J Antimicrob Chemother* 2001; 47: 589-98
21. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. *Infect Control Hosp Epidemiol* 2001; 22: 640-6
22. J. Brunke, T. Riemann, I. Roschke, 30 days antimicrobial efficacy of non-leaching central venous catheters (Poster 063), *Critical Care* 2016, Volume 20 Suppl 2